The virus often produces either no symptoms or mild ones like fever in adults, but an outbreak in Brazil has been linked to a rare birth defect that causes a newborn's heads to be smaller and brain development issues. Outbreaks also have been reported in parts of Africa, Southeast Asia, the Pacific Islands, and the Americas. Pest control companies in Texas are...» Read More
GlaxoSmithKline can fuggedaboutit. If New York radio listeners have a problem with the company's new ad campaign for Nicorette, then how will it possibly play in Peoria?
For Cephalon, a company in Frazer, Pa., whose business tactics have attracted federal attention, the approval for jet lag is part of a plan to extend patent protection for its core franchise in stay-awake drugs.
GlaxoSmithKline is getting into the movie business, pursuing an unusual and most likely controversial strategy to increase interest in a weight-loss drug. The New York Times reports.
No one in their right mind, especially in this economy, likes to see someone lose their job. (Well, unless you really can't stand the person.) But, on the other hand, when you hear the top exec of the world's biggest drug company talk candidly about how much fat there was (is?) at Pfizer, can you really blame him for swinging the ax?
With the home medical equipment market expected to expand at a steady clip over the next few years, consumer electronics companies are eager to expand their minimal presence.
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
Time magazine's Man of the Year Ben Bernanke gave a speech this past weekend, and at first I thought he was defending the excessively loose monetary policy that led to the recent crisis.
Well, that didn't take long. It's only the first business day of the new year and big pharma's already gettin' down to business. Novartis is buying the rest of its Swiss neighbor Alcon for a cool $38.5 billion.
Usually I wouldn’t devote a blog to a biotech with a market value of approximately $86 million. But when your personal story goes Hollywood—as in mega-watt stars like Harrison Ford and Brendan Fraser playing the lead roles in the movie—then you get a blog.
At the heart of the health care debate is the question of whether it’s possible to cut medical costs without harming patients. What has happened in Richmond, Virginia helps to answer that question.
When I blogged last week about GlaxoSmithKline using the word “suck” in its new Nicorette ad campaign I thought it would be a one and done thing.
I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.
Our health care system suffers from soaring costs and uneven quality. For health reform to be a success, it needs to make major progress on those problems. Here's a guide to the coming negotiations between the House and Senate aimed at closing the gaps between their two versions of reform legislation.
It's New Year's resolution time, so it's no surprise to see a sudden increase in commercials and ads for stop-smoking products. Pfizer's been heavily pushing its challenged Chantix and the other day I saw a commercial for GlaxoSmithKline's Nicorette that nearly made my jaw drop.
As senators made their way to Capitol Hill this weekend, a confluence of meteorological conditions conspired to dump nearly two feet of snow on Washington, DC. Unlike the decisions being made under the Capitol dome, we’ll soon dig ourselves out from the mountains of snow.
This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.
The New York Times reports on some of the hidden compromises in the final version of the Senate's health care reform bill.
If you have had the misfortune to follow this debate as it grinds through the Senate, several thoughts come to mind.
There is nothing in this bill that changes our views at Soleil regarding the health care stocks we have been recommending.
I went to the beleaguered Genzyme manufacturing plant in Allston, MA yesterday to get briefed on what exactly happened/is happening there for background ahead of my interview today with the CEO.